Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

113.75 UNCHANGED
Streaming Delayed Price Updated: 3:14 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
4 Analysts Assess Arcellx: What You Need To Know ↗
 
Via Benzinga
News headline image
(ACLX) - Analyzing Arcellx's Short Interest ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 14 Analyst Recommendations For Arcellx ↗
 
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
14 Analysts Have This To Say About Arcellx ↗
 
Via Benzinga
News headline image
Analyst Expectations For Arcellx's Future ↗
 
Via Benzinga
News headline image
Navigating 7 Analyst Ratings For Arcellx ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Arcellx ↗
 
Via Benzinga
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Arcellx Director Sells 6,000 Shares for $450,000 ↗
A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Small-Cap M&A Boom of 2026: How $440 Billion in Dry Powder and Rate Cuts Are Remaking the Market
As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
4 Analysts Assess Arcellx: What You Need To Know ↗
 
Via Benzinga
News headline image
Assessing Arcellx: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Arcellx (ACLX) Q2 Revenue Drops 72% ↗
Via The Motley Fool
News headline image
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
News headline image
Arcellx Stock Earns 82 Relative Strength Rating ↗
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
News headline image
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.